Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.520
-0.025 (-1.62%)
Streaming Delayed Price
Updated: 3:57 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
Next >
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
May 11, 2023
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform
From
OKYO Pharma LTD
Via
GlobeNewswire
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
May 09, 2023
Via
ACCESSWIRE
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
April 25, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Via
ACCESSWIRE
Notice of General Meeting and Publication of Circular
April 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Notice of Intention to Delist From The London Stock Exchange
April 04, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 30, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Today Announces Director Acquires Shares
March 29, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
OKYO Pharma Announces PDMR Dealing
March 24, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
March 16, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
March 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
March 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
March 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
February 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board
February 23, 2023
World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
February 21, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
December 30, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
December 22, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO to Participate at Biotech Showcase
December 21, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
December 06, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited - Change of Auditor
December 01, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited – PDMR dealing
November 24, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
November 21, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
November 10, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
September 08, 2022
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.